Researchers at Ningbo Combireg Pharmaceutical Technology Co. Ltd. and Versitech Ltd. have described benzothiazole compounds reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 60 Degrees, AB Science, Astex, Atamyo, Beigene, Biophytis, Gilead, GSK, Intelgenx, Merck & Co., Otsuka, Pfizer, Rhythm, Viiv.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Arcturus, Arcutis, Aspargo, Astellas, Avacta, Caliway, Cerevance, Geovax, Immpact, Indaptus, Iveric, Revolution, Saol, Scancell.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Almirall, Argenx, Ascendis, Astrazeneca, Daiichi Sankyo, Hemogenyx, Iovance, Merck, Moderna, PTC, UCB, Vertex.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anavex, Asieris, Biohaven, Coeptis, Edgewise, Scilex, Vincerx.

Research at Medshine Discovery Inc. has led to the development of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors potentially useful for the treatment of SARS-CoV-2 infection (COVID-19).

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Affimed, Arcutis, Biontech, Cygenica, Eikon, Gain, Hoth, Moderna, Pfizer.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Acelyrin, Aerami, Aim, Algo, Altimmune, Anokion, Artiva, Arrowhead, Astrazeneca, Avalyn, Curevac, Day One, Dianthus, Foresee, GSK, Humacyte, Hutchmed, IO Biotech, Lisata, Lyra, Mindmed, Myeloid, Neurocrine, Nextcure, Nuvectis, Ose, Replicate, RS Oncology, Sorrento, Sparrow, Valbiotis, Vistagen.

Instead of the bivalent COVID-19 vaccines comprising both the original and omicron BA.4/BA.5 SARS-CoV-2 strains that have been in use in the U.S. since April, the CDC’s Advisory Committee for Immunization Practices voted 13-1 Sept. 12 to recommend the universal use of updated monovalent XBB-containing COVID-19 vaccines as authorized or approved by the FDA.